While the issue has fallen from the headlines after several moves to cap the cost, some patients with diabetes still often ...

Lilly has taken a non-exclusive license to deploy Dexcom’s CGM systems – which include app-based remote monitoring and alarm functions – in pen- and pump-based insulin systems that form the ...

Lilly is already using the technology to analyse data from continuous glucose monitors, insulin pumps and real world information, to improve the experience of people with diabetes, and build a ...

They say over the past two-plus decades, they’ve overpaid millions of dollars for insulin through their employees’ health plans. So, they’re suing the manufacturers including Lilly ...

The global Insulin Delivery Devices Market was valued at USD 30.9 billion in 2022 and is expected to grow significantly, ...

Sanofi's Merilog wins FDA approval as the first rapid-acting insulin biosimilar to Novolog, offering a new option for diabetes management.

You can't call what happened with stocks last week a huge win, but it was a win. The Standard & Poor's 500 Index finished the week up 1.5% at 6,114.63. The index flirted with but failed to hit a ...

You can't call what happened with stocks last week a huge win, but it was a win. The Standard & Poor's 500 Index finished the ...

Household), By Types (Insulin Pumps, Insulin Pens, Insulin Syringes, Basal or Long Acting Insulins, Bolus or Fast-Acting Insulins), By Segmentation analysis, Regions and Forecast to 2033.